This week in drug discovery (9-13 September)
News round-up for 9-13 September by DDW Senior Digital Content Editor Diana Spencer.
This week, DDW has opened registrations for its webinar ‘The latest advancements driving neuroscience drug discovery research’, so our news highlights focus on developments in neuroscience, including a novel drug that has been shown to reduce neuronal death, and a potential disease-modifying treatment for dementia.
The top stories:
The latest advancements driving neuroscience drug discovery
In this webinar on 30 September, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX.
Industry/research collaboration to automate human brain studies
The Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children’s Hospital has advanced its research capabilities with the implementation of an automation platform for human cellular model generation, maintenance, and characterisation, in collaboration with Automata Technologies.
Novel drug reduces neuronal death in neurodegenerative disease
New research has shown that Ellorarxine, a novel drug compound developed by biotech Nevrargenics, provides a robust neuroprotective effect and reduces neuronal death in cell models of neurodegenerative disease.
Study offers possible treatment for frontotemporal dementia
Vesper Bio has completed a Phase I study for its lead candidate, VES001, a potentially disease-modifying treatment for frontotemporal dementia patients with mutations in the progranulin gene (FTD(GRN)).
mPTP Inhibitors block mitochondrial dysfunction in ALS
NRG Therapeutics has been awarded a non-dilutive grant from Target ALS Foundation to support its discovery programme for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or motor neurone disease.
